Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 12;14(1):137.
doi: 10.1038/s41408-024-01114-7.

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Rajshekhar Chakraborty  1 , Heloise Cheruvalath  2 , Anannya Patwari  2 , Aniko Szabo  2 , Carolina Schinke  3 , Binod Dhakal  2 , Suzanne Lentzsch  4 , Anita D'Souza  2 , Ghulam Rehman Mohyuddin  5 , Kelley Julian  5 , Shonali Midha  6 , Patrick Costello  6 , Martin Kaiser  7 , Melissa Ng Liet Hing  8   9 , Simon J Harrison  8   9 , Edward R Scheffer Cliff  8   9 , Meera Mohan  2
Affiliations

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Rajshekhar Chakraborty et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

RC: Consulting/Advisory Board-Janssen, Sanofi, Adaptive Biotech. SL: Consultant and/or Advisor for Adaptive Biotechnologies, Alexion Therapeutics, Bristol-Meyers-Squibb, Caelum Biosciences, Janssen Pharmaceuticals, Karyopharm Therapeutics, Oncopeptides AB, GSK, Abbvie, Janssen, Pfizer, and Takeda Pharmaceutical Company; receives research funding from Celgene, Inc., Sanofi, Zentalis; received honoraria from Clinical Care Options and Regeneron Pharmaceuticals; and has Royalties/Patents with Caelum Biosciences. In addition, SL has a patent CAEL-101 with royalties paid to Columbia University. AD: Institutional research funding from AbbVie, Caelum, Janssen, Novartis, Prothena, Sanofi, Takeda, and TeneoBio; advisory board fees from BMS, Pfizer, and Janssen; and consulting fees from Prothena and Janssen. BD: Consultant-BMS, Genentech, Janssen, Karyopharm, Natera, Pfozer. SH: Consultant-Celgene, Genentech, Janssen, Novartis. MK: Honoraria: Janssen, Takeda, AbbVie, and Sanofi; consulting or advisory role: AbbVie, GSK, Janssen, Pfizer, Seattle Genetics, Takeda, Adaptive and Poolbeg Pharma. Research funding: BMS/Celgene (to institution) and Janssen (to institution). MM: Institutional Research Funding: Sanofi S.A, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Ionis Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Sanofi S.A, and Amgen Inc; Consultancy: Sanofi S.A, Bristol-Myers Squibb Company, and Pfizer; Honorarium: Blood Cancer Today, MJH life sciences. The remaining authors declare no relevant financial conflicts of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve for progression-free survival from discontinuation of bispecific antibody in patients with relapsed/refractory myeloma.
Fig. 2
Fig. 2
Swimmer plot for outcomes in all 23 patients who discontinued bispecific antibodies for a reason other than progression or death and had at least 3 months of follow-up after drug discontinuation, commencing at the time of discontinuation.
See this image and copyright information in PMC

References

    1. Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel J, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495–505. 10.1056/NEJMoa2203478 - DOI - PMC - PubMed
    1. Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259–67. 10.1038/s41591-023-02528-9 - DOI - PMC - PubMed
    1. D’Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2022;40:3576–86. 10.1200/JCO.22.01504 - DOI - PMC - PubMed
    1. Jagannath S, Richter J, Dhodapkar MV, Hoffman JE, Lee HC, Suvannasankha A, et al. Patterns of response to 200 Mg linvoseltamab in patients with relapsed/refractory multiple myeloma: longer follow-up of the linker-MM1 study. Blood. 2023;1424746. 10.1182/blood-2023-177968 - DOI
    1. Bar N, Mateos MV, Ribas P, Hansson M, Paris L, Hofmeister CC, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) × CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study. Blood. 2023;142:2011. 10.1182/blood-2023-180013 - DOI

Publication types

Substances

LinkOut - more resources